Navigation Links
Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine

linical studies."

About Dysmenorrhea

Dysmenorrhea is characterized by recurrent uterine cramping and pain before and during menses. This common, painful women's health condition seriously affects 12% of all menstruating women in the U.S. between the ages of 20 and 45, or about 5.6 million women. It is estimated to account for 600 million lost work hours and approximately $2 billion in lost productivity annually. Current treatments address the pain but not the underlying problem. Columbia's hypothesis is that administering lidocaine vaginally, using its proprietary bioadhesive delivery system (BDS) technology, can minimize or prevent the severe cramping that results in the debilitating pain of dysmenorrhea.

About Columbia Laboratories

Columbia Laboratories, Inc. is a is a specialty pharmaceutical company focused on developing and marketing products for the women's healthcare and endocrinology markets using its novel bioadhesive drug delivery technology. Columbia markets CRINONE(R) 8% (progesterone gel) and PROCHIEVE(R) 8% (progesterone gel) in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT(R) (testosterone buccal system) for the treatment of hypogonadism in men. For more information, please visit www.columbialabs.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, and clinical research programs, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially fr
'"/>




Page: 1 2 3

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:12/1/2008)...ll/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ...world,s leading medical journals, results of clini...imental compound tasimelteon (VEC-162). The publi...in agonist tasimelteon (VEC-162) for transient ins...olled multicentre trials." Results are reported fr...
(Date:12/1/2008)...wo-way switch that, if turned off, causes lymphati...y lose their identity and become more like blood e... Scientists at St. Jud...t a certain differentiated cell type is so ready t...t expression of a gene called Prox1 to dissuade ...
(Date:12/1/2008)...GeoVax Labs, Inc.,(OTC Bulletin Board: GOVX), an ...man vaccines for diseases caused by HIV-1 (Human I...s, announced today that the launch of its Phase 2a...ites across North and South America.,These trials...Institutes of,Health (NIH), and the HIV Vaccine T...
(Date:11/28/2008)...l/ -- Eli Lilly and Company,(NYSE: LLY ) has wi...A) from,the U.S. Food and Drug Administration (FD...ement of chronic pain. Lilly plans to resubmit the...ta from a recently completed positive study,in ch...e decision does not affect duloxetine,s FDA-approv...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 1Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 2Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 3Forterus Inc Announces Stock Buyback 29598 1Forterus Inc Announces Stock Buyback 29598 2The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 1The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 2The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 3The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 4Innovative Wellness Project Launched in Four Maine School Districts 29592 1Innovative Wellness Project Launched in Four Maine School Districts 29592 2
(Date:12/2/2008)... 2 The Healthcare group at,Frost ... is pleased to announce that,it will be hosting a...,sub-Saharan Africa on Friday 12 December at 16h0...om.com/cgi-bin/prnh/20081117/FSLOGO ) , Med...services is a,relatively novel concept in most su...
(Date:12/2/2008)...athon Health, a leading provider of onsite health ...hat New Balance, the athletic products company, ha...nd manage onsite health clinics and to provide hea...in Maine , Burlington, VT...ading provider of onsite employee health services ...
(Date:12/2/2008)... many families, the problem with the holidays is f...ight into how caregivers of aging parents can brin...experience. , San Mateo, ...he stress of the holiday season is family, especia...xpert Esther Koch , founder of Encore Management...
(Date:12/2/2008)...ional Non-profit Launches Age-related Macular Dege...ost to Eligible Patients and Free Eye-Healthy Cook... (Vocus) December 2, 2008 -- "Do You See What...isease known as Age-related Macular Degeneration (... ,Picture this…. a large black hole in the ...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3
...ewed journal of American Cancer Society) reveals t...t clinically significant screening// criteria for ...uding major depression and post-traumatic stress d...ally all of the women admitted have been experienc...
...hat has FDA approval for treating rheumatoid arthr...ith juvenile rheumatoid// arthritis, according to ...ge of Rheumatology Annual Scientific Meeting in Wa...adalimumab, currently used to treat adults with mo...
...detect synacthen, which when injected simulates th...steroid. This is// most common in sports where spo...-enhancing tool. Synacthen and injecting performan... other than medical treatment is banned. Though ...
...und that pregnant women with systemic lupus are at...ions compared to normal// pregnant women. The stu...ted nationwide covering more than 18 million women...n with systemic lupus should be considered a high-...
Other Medicine News:Health News:Breast Cancer Patients Suffer From Psychological Problems 2Health News:Adalimumab Proves Effective for Children with Juvenile Rheumatoid Arthritis 2Health News:Sports Cheats Beware - New Test To Detect Synacthen Found 2Health News:Pregnant Women With Lupus Are At Greater Risk 2Health News:Pregnant Women With Lupus Are At Greater Risk 3
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists.
...fety Knife with BD Xstar Blade includes a speciall...tects the blade in prodedure and handling. The Xs...ess for manufacturing surgical blades. This propr...nsistency. The arch style, single-bevel geometry ...
Electric high speed system.
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm.
Medicine Products: